Connect your AI

CONMED CNMD 2031

2031 at other companies

MedtronicMDT

——

IAR

Integra LifeSciencesIART

——

SolventumSOLV

——

Bausch + LombBLCO

——

Other financials

Income statement

Revenue$317.0M-1.3%

Gross profit$183.4M+3.2%

Operating income$25.4M+59.3%

Net income$13.8M+129%

EPS (diluted)$0.45+137%

Balance sheet

Cash & equivalents$35.0M-1.3%

Total debt$862.6M-3.6%

Total equity$1.0B+4.1%

Total assets$2.3B+0.8%

Cash flow

Operating cash flow$13.5M-67.6%

CapEx$2.9M-23.5%

Free cash flow$10.6M-72.0%

Valuation

Market cap$1.07B-34.0%

Enterprise value$1.89B-23.5%

P/E19.4×+5.8×

P/S0.8×-0.5×

Profitability

Gross margin55.2%-1.0pp

Operating margin8.2%-5.6pp

Net margin4%-5.0pp

FCF margin9%-3.5pp

Returns & leverage

Return on equity5.5%-7.5pp

Debt / equity0.8×-0.1×

Current ratio2.3×0.0×

Where this comes from

Reported directly by CONMED in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive.

The official record: CONMED’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about CONMED's 2031.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is CONMED's 2031?: CONMED (CNMD) reported 2031 of $42.06M in Q1 2026.
How has CONMED's 2031 changed year-over-year?: CONMED's 2031 increased by 3.6% year-over-year, from $40.62M to $42.06M.